ClinicalTrials.gg
Not yet recruitingNCT07701213BFR-IDAUpdated Jul 14, 2026

Blood Flow Restriction and Aerobic Exercise in Iron Deficiency Anemia

An interventional study of aerobic exercise + blood flow restriction and aerobic exercise in Iron Deficiency Anaemia, sponsored by Cairo University. Not yet recruiting. Open to participants aged 19 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
19 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Anemia, Iron-Deficiency by Cairo University — 4 open to participants now, 4 under way, none of them phase 3. Anemia, Iron-Deficiency · Cairo University.

Started
2026
with 3 others
No phase
5 of 11
2 open now
Registered
11th of 11
by date

Among the 11 studies in Anemia, Iron-Deficiency by Cairo University, this one is one of 4 that started in 2026, is one of 5 with no phase, and was the 11th registered.

Anemia, Iron-Deficiency

602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

4 of the 11 studies in Anemia, Iron-Deficiency by Cairo University are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 19 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Anemia, Iron-Deficiency by Cairo University, or all of them as a file.
02

Study summary

Preventing iron deficiency anemia is essential for strengthening adolescent health and ensuring their full development. Strategies such as improving nutrition, expanding the availability of iron-fortified products, implementing pharmacological prevention, and raising awareness play a crucial role in addressing this issue.

Read the detailed description

Anemia is a global public health problem affecting both developing and developed countries at all ages, with major consequences for human health as well as social and economic burden. Iron deficiency affects more than 2 billion people world wide, and iron deficiency anemia (IDA) remains to be the top cause of anemia.

For decades, blood flow restriction (BFR), originating from Japan, has become one of the most popular techniques in physiotherapy. To perform the BFR technique, a controlled tourniquet is performed, generating a gradual mechanical pressure just below it, affecting blood flow (both arterial and venous) and generating a hypoxia in the restricted area. For the realization of the tourniquet, mechanical cuffs are used, which are inflated and regulate the pressure generated in the compression zone, although nylon or elastic cuffs are also used for the realization of the tourniquet.

03

Conditions studied

  • Iron Deficiency Anaemia

Keywords

  • Iron Deficiency Anemia
  • blood flow restriction
04

Who can participate

Ages eligible
19 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. more than 8 and less than 12 in females.
  2. Age: 19-25 year.
  3. ranging from 25 to 29.9 kg/m2.
  4. No existing inflammatory conditions including rheumatoid arthritis disorders of the lower extremities.
  5. Physical activity level less than 150 min per week

Exclusion criteria

Exclusion Criteria:

  1. unstable hypertension, venous thromboembolism, hypercoagulable states, varicose veins, pregnancy, and hemophilia.
  2. inherited or acquired red cell disorders (haemoglobinopathies).
  3. acute or chronic infections (malaria, tuberculosis, ),.
  4. severe anemia ( \<8 g/dL).
  5. History of cardiovascular diseases.
  6. Nutritional anemia (B12/folate)
  7. Pregnancy.
  8. Peripheral arterial disease.
  9. Intermittent claudication.
  10. Non smokers
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Aerobic Exercise + Blood Flow Restriction

    25 female will receive blood flow restriction with low intensity aerobic exercise participated in 3 months exercise training protocol, which included three walking training sessions per week on a treadmill set at a speed 3 km/h. They experienced 3 session/week and each session include 5-10 minutes warming up and five training sets (each lasting 2 min) with a 1 min rest period between each exercise session and ended with 5-10 minutes cooling down A pressure of between 140 and 200 mmHg was applied using a sphygmomanometer cuff placed at the thigh of the BFR group.

    Device: aerobic exercise + blood flow restriction

  • Active comparator
    Aerobic Exercise

    25 subject participated in 3 months exercise training protocol, which included three walking training sessions per week on a treadmill set at a speed 3 km/h. They experienced 3 session/week and each session include 5-10 minutes warming up and five training sets (each lasting 2 min) with a 1 min rest period between each exercise session and ended with 5-10 minutes cooling down.

    Procedure: aerobic exercise

Interventions

  • Deviceaerobic exercise + blood flow restriction

    Twenty five females will be subjected to supervised blood flow restriction combined with aerobic exercise program. participated in 3 months exercise training protocol, which included three walking training sessions per week on a treadmill set at a speed 3 km/h. They experienced 3 session/week and each session include 5-10 minutes .A pressure of between 140 and 200 mmHg was applied using a sphygmomanometer cuff placed at the thigh of the BFR group. The pressure of the cuff was increased until the participants adapted to the restriction stimulus during the early phase of training, and this pressure was maintained used during the training protocol. The strap pressure was increased by 10 mmHg per week, such that it reached 200 mmHg by the end of 12th week. The pressure on the thigh strap was abruptly released after five completions of the exercise set.

  • Procedureaerobic exercise

    participated in 3 months exercise training protocol, which included three walking training sessions per week on a treadmill set at a speed 3 km/h. They experienced 3 session/week and each session include 5-10 minutes warming up and five training sets (each lasting 2 min) with a 1 min rest period between each exercise session and ended with 5-10 minutes cooling down.

06

What researchers measure

Primary outcomes

  1. haemoglobin concentration

    Time frame: Baseline and 12 weeks

  2. Serum ferritin level

    Time frame: Baseline and at 12 weeks

  3. Haematocrit

    Time frame: Baseline and at 12 weeks

  4. Red blood cell (RBC) count

    Time frame: baseline and at 12 week

  5. Mean corpuscular volume (MCV)

    Time frame: baseline and at 12 week

  6. Mean corpuscular haemoglobin (MCH)

    Time frame: baseline and at 12 week

Secondary outcomes

  1. Functional capacity assessed using the Incremental Shuttle Walk Test (ISWT)

    Time frame: baseline and at 12 week

  2. Quality of life assessed using the SF-36 questionnaire

    Time frame: baseline and at 12 week

  3. Estimated maximal oxygen consumption (VO₂max) derived from the ISWT

    Time frame: baseline and at 12 week

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Oct 2026, 3 months later.

Of 133 non-industry interventional studies with no phase under Anemia, Iron-Deficiency, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 3 months is below that.

Counting every sponsor, half of 142 studies reached it within 11 months; a quarter within 3 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Jul 14, 2026
StartEst.
Jul 25, 2026
Primary completionEst.
Oct 30, 2026
CompletionEst.
Nov 5, 2026
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07701213
Lead sponsor
Cairo University
Responsible party
noha sameh (assistant lecturer, Cairo University) — Principal investigator
First posted
Jul 14, 2026
Start date
Jul 25, 2026 (estimated)
Primary completion
Oct 30, 2026 (estimated)
Completion
Nov 5, 2026 (estimated)
Last update
Jul 14, 2026

Study contacts

noha sameh donia, assisstant lecturer
Contact
nohasameh92.ns@gmail.com
01275600448

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion